StevenAlanFischkoffMD

PubMed

• 5 citations
  Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
  Carl Spana, Robert Jordan, Steven Fischkoff> ;Diabetes, Obesity & Metabolism. 2022 Jun 1
• 22 citations
  Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with periph...
  Stephanie C. Wu, Richard Pollak, Robert G. Frykberg, Wei Zhou, Maha Karnoub, Vladimir Jankovic, Steven Fischkoff, Denesh Chitkara> ;International Wound Journal. 2017 Jan 30
• 79 citations
  Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study $
  Fred D. Lublin, James D. Bowen, John Huddlestone, Marcelo Kremenchutzky, Adam F. Carpenter, John R. Corboy, Mark S. Freedman, Lauren B. Krupp, Corri Paulo, Robert J. H...> ;Multiple Sclerosis and Related Disorders. 2014 Nov 1
• 48 citations
  Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.
  Lloyd Mayer, William M. Pandak, Gil Y. Melmed, Stephen B. Hanauer, Kristine Erikson Johnson, Denise Payne, Herbert Faleck, Robert J. Hariri, Steven Fischkoff> ;Inflammatory Bowel Diseases. 2013 Mar 1
• 186 citations
  Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
  Stephen M. Ansell, Steven M. Horwitz, Andreas Engert, K. Khan, Thomas Lin, Roger Strair, Tibor Keler, Robert F. Graziano, Diann Blanset, Michael Yellin, Steven Fischko...> ;Journal of Clinical Oncology. 2007 Jul 1
• Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma.
  Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M, Fischkoff S, Nichol G> ;J. Clin. Oncol.. 2006-06-20
• Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormon...
  Small E, Higano C, Tchekmedyian N, Sartor O, Stein B, Young R, Vestal J, Moseley W, Fischkoff S, Lowy I> ;J. Clin. Oncol.. 2006-06-20
• Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma.
  Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O'Day S, Nichol G, Yellin M> ;J. Clin. Oncol.. 2005-06-01
• 257 citations
  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
  Edward A. Panacek, John C. Marshall, Timothy E Albertson, David H. Johnson, Steven B. Johnson, Rodger D. MacArthur, Mark A. Miller, William T. Barchuk, Steven Fischkof...> ;Critical Care Medicine. 2004 Nov 1
• 937 citations
  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoi...
  Edward C. Keystone, Arthur Kavanaugh, John T. Sharp, Hyman Tannenbaum, Ye Hua, Leah S. Teoh, Steven A. Fischkoff, Elliot Chartash> ;Arthritis and Rheumatism. 2004 May 1
• 400 citations
  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthriti...
  Daniel E. Furst, Michael Schiff, Roy Fleischmann, Vibeke Strand, C. Birbara, Daniele Compagnone, Steven A. Fischkoff, Elliot Chartash> ;The Journal of Rheumatology. 2003 Dec 1
• 215 citations
  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis...
  Michael H. Weisman, Larry W. Moreland, Daniel E. Furst, Michael E. Weinblatt, Edward C. Keystone, Harold E. Paulus, Leah S. Teoh, Raja B. Velagapudi, Peter Noertersheu...> ;Clinical Therapeutics. 2003 Jun 1
• 1364 citations
  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: ...
  Michael E. Weinblatt, Edward C. Keystone, Daniel E. Furst, Larry W. Moreland, Michael H. Weisman, C. Birbara, Leah A. Teoh, Steven A. Fischkoff, Elliot Chartash> ;Arthritis and Rheumatism. 2003 Jan 1
• 32 citations
  A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
  James Gallagher, Charles J. Fisher, Bruce Sherman, Mark A. Munger, Bruce Meyers, Travis Ellison, Steven Fischkoff, William T. Barchuk, Leah Teoh, Raja B. Velagapudi> ;Intensive Care Medicine. 2001 Jul 1
• 10 citations
  Eosinophil differentiation of human umbilical cord mononuclear cells and prolonged survival of mature eosinophils by murine EL-4 thymoma cell conditioned medium.
  Rosa M. Ten, Joseph H. Butterfield, Hirohito Kita, Deborah A. Weiler, Steven A. Fischkoff, Teruko Ishizaka, Colin J. Sanderson, Gerald J. Gleich> ;Cytokine. 1991 Jul 1
• 27 citations
  Glucocorticoid and progestin regulation of eosinophil chemotactic factor and complement C3 in the estrogen-treated rat uterus.
  Howe Rs, Lee Yh, S A Fischkoff, Teuscher C, C. R. Lyttle> ;Endocrinology. 1990 Jun 1
• 6 citations
  Characterization of sublines of HL-60 human leukemia cells resistant to induction of differentiation by butyric acid.
  Steven A. Fischkoff, M. C. Hoessly, R. M. Rossi> ;Leukemia. 1990 Apr 1
• 11 citations
  Lineage directed HL-60 cell sublines as a model system for the study of early events in lineage determination of myeloid cells.
  Steven A. Fischkoff, Randall M. Rossi> ;Leukemia Research. 1990 Jan 1
• 16 citations
  Factors responsible for variable reported lineages of HL-60 cells induced to mature with butyric acid
  M. C. Hoessly, R. M. Rossi, Steven A. Fischkoff> ;Cancer Research. 1989 Jul 1
• 56 citations
  Graded increase in probability of eosinophilic differentiation of HL-60 promyelocytic leukemia cells induced by culture under alkaline conditions.
  Steven A. Fischkoff> ;Leukemia Research. 1988 Jan 1
• 14 citations
  Induction of differentiation of the human leukemia cell line, KU812
  Steven A. Fischkoff, Kenji Kishi, William R. Benjamin, Randall M. Rossi, Michel C. Hoessly, James A. Hoxie, Cary M. Seals, Linda Anderson, Teruko Ishizaka, John Hakimi> ;Leukemia Research. 1987 Jan 1
• 24 citations
  Synthesis of eosinophil-associated enzymes in HL-60 promyelocytic leukemia cells.
  Steven A. Fischkoff, Glenn E. Brown, Avrom Pollak> ;Blood. 1986 Jul 1
• 45 citations
  Switch in Differentiative Response to Maturation Inducers of Human Promyelocytic Leukemia Cells by Prior Exposure to Alkaline Conditions
  Steven A. Fischkoff, Margaret E. Condon> ;Cancer Research. 1985 May 1
• 26 citations
  Development of membrane-potential responsiveness by myeloid leukemia cells during neutrophilic differentiation.
  Glenn E. Brown, Steven A. Fischkoff, José V. Ordóñez> ;Biochemical and Biophysical Research Communications. 1984 Sep 28
• 6 citations
  Decreased activity of acetyl-CoA carboxylase during chemically induced neutrophilic differentiation of human promyelocytic leukemia cells.
  Steven A. Fischkoff, Gary C. Papuchis, Wayne A. Nickols> ;Journal of Cellular Biochemistry. 1984 Jan 1
• Join now to see all